A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in the 100% Medicare Fee-For-Service (FFS) Data (2009-2020)
Conditions: Prostatic Neoplasms, Castration-Resistant
Sponsor: Pfizer



Enzalutamide
C3431046 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 09 August 2022
PFIZER CONFIDENTIAL
Page 44 of 47
15. REFERENCES
1.
National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. 2021; 
https://seer.cancer.gov/statfacts/html/prost.html. Accessed July 21, 2021.
2.
National Cancer Institute. Prostate cancer treatment: health professional version. 
2016; http://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq. Accessed July 
21, 2021.
3.
Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate 
cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192.
4.
He L, Fang H, Chen C, et al. Metastatic castration-resistant prostate cancer: 
Academic insights and perspectives through bibliometric analysis. Medicine 
(Baltimore). 2020;99(15):e19760.
5.
National Comprehensive Cancer Network. Prostate Cancer. . 2021; Version 
2.2021:https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 
July 21, 2021.
6.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic 
Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-746.
7.
Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-
naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 
PREVAIL study. European urology. 2017;71(2):151-154.
8.
Moreira DM, Howard LE, Sourbeer KN, et al. Predicting Time From Metastasis to 
Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. 
Clin Genitourin Cancer. 2017;15(1):60-66 e62.
9.
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus
placebo plus prednisone in chemotherapy-naive men with metastatic castration-
resistant prostate cancer (COU-AA-302): final overall survival analysis of a 
randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 
2015;16(2):152-160.
10.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone 
plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-
1512.
11.
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in 
metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
12.
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer 
without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
13.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate 
cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
14.
Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line 
therapy for patients with metastatic castration-resistant prostate cancer: a randomized 
phase III trial—FIRSTANA. Journal of Clinical Oncology. 2017;35(28):3189-3197.
15.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for 
castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
16.
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in 
metastatic prostate cancer. New England Journal of Medicine. 2013;369(3):213-223.

Enzalutamide
C3431046 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 09 August 2022
PFIZER CONFIDENTIAL
Page 45 of 47
17.
de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant 
prostate cancer. N Engl J Med. 2020;382(22):2091-2102.
18.
Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-
resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of 
Clinical Oncology. 2020;38(32):3763.
19.
Astellas Pharma US. XTANDI [package insert]. 2012; 
https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf. Accessed July 21, 2021.
20.
Janssen Global Services LLC. ZYTIGA [package insert]. 2011; 
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-
information/ZYTIGA-pi.pdf. Accessed July 21, 2021.
21.
George DJ, Sartor O, Miller K, et al. Treatment Patterns and Outcomes in Patients 
With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice 
Setting in the United States. Clin Genitourin Cancer. 2020;18(4):284-294.
22.
Chowdhury S, Bjartell A, Lumen N, et al. Real-World Outcomes in First-Line 
Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer 
Registry. Target Oncol. 2020;15(3):301-315.
23.
Ternov et al. EAU 2021: Fatigue, Quality-of-Life and Metabolic Changes in Men 
Treated With Enzalutamide Versus Abiraterone Plus Prednisone (HEAT): A 
Randomized Trial. 2021; https://www.urotoday.com/conference-highlights/eau-
2021/eau-2021-prostate-cancer/130754-eau-2021-fatigue-quality-of-life-and-
metabolic-changes-in-men-treated-with-enzalutamide-versus-abiraterone-plus-
prednisone-heat-a-randomized-trial.html. Accessed August, 2021.
24.
Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and 
abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a 
multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 
2019;20(12):1730-1739.
25.
Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B. Abiraterone or Enzalutamide 
in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. Prostate. 
2017;77(6):639-646.
26.
Fang M, Nakazawa M, Antonarakis ES, Li C. Efficacy of Abiraterone and 
Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A 
Trial-Level Meta-Analysis. Prostate Cancer. 2017;2017:8560827.
27.
McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S. Systematic 
review and network meta-analysis of treatments for chemotherapy-naive patients with 
asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. 
Value in Health. 2018;21(10):1259-1268.
28.
Raju R, Sahu A, Klevansky M, Torres J. Real-World Data on Outcomes in Metastatic 
Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or 
Enzalutamide: A Regional Experience. Front Oncol. 2021;11:656146.
29.
Scailteux L-M, Campillo-Gimenez B, Kerbrat S, et al. Overall Survival Among 
Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under 
Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014–2018 
French Population Study (the SPEAR Cohort). Am J Epidemiol. 2021;190(3):413-
422.

Enzalutamide
C3431046 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 09 August 2022
PFIZER CONFIDENTIAL
Page 46 of 47
30.
Schoen MW, Carson KR, Luo S, et al. Survival of veterans treated with enzalutamide 
and abiraterone in advanced prostate cancer. In: Wolters Kluwer Health; 2021.
31.
Soleimani M, Zou K, Sunderland K, et al. Effectiveness of first-line abiraterone 
versus enzalutamide among patients >/=80 years of age with metastatic castration-
resistant prostate cancer: A retrospective propensity score-weighted comparative 
cohort study. Eur J Cancer. 2021;152:215-222.
32.
Tagawa ST, Ramaswamy K, Huang A, et al. Survival outcomes in patients with 
chemotherapy-naive metastatic castration-resistant prostate cancer treated with 
enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021.
33.
Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB. Outcomes 
Among African American and Non-Hispanic White Men With Metastatic Castration-
Resistant Prostate Cancer With First-Line Abiraterone. JAMA network open. 
2022;5(1):e2142093-e2142093.
34.
Jarow JP, LaVange L, Woodcock J. Multidimensional Evidence Generation and FDA 
Regulatory Decision Making: Defining and Using "Real-World" Data. JAMA. 
2017;318(8):703-704.
35.
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and 
what can it tell us. N Engl J Med. 2016;375(23):2293-2297.
36.
U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence 
program. 2018; https://www.fda.gov/media/120060/download. Accessed September 
27, 2019.
37.
US Food and Drug Administration. Submitting Documents Using Real-World Data 
and Real-World Evidence to FDA for Drugs and Biologics. Draft Guidance for 
Industry. 2019; https://www.fda.gov/media/124795/download.
38.
Administration SS. GN 00304.005 Preferred Evidence of Death. 2019; TN 20 (04-
19):https://secure.ssa.gov/poms.nsf/lnx/0200304005. . Accessed July 21, 2021.
39.
Administration SS. GN 00304.001 Proof of Death Requirements. Program 
Operations Manual System (POMS) 2020; TN 21 (10-
20):https://secure.ssa.gov/poms.NSF/lnx/0200304001. Accessed July 21, 2021.
40.
Administration SS. Requesting SSA’s Death Information. 2021; 
https://www.ssa.gov/dataexchange/request_dmf.html. Accessed July 21, 2021.
41.
Center CRDA. Data Documentation- Master Beneficiary Summary File Base. 2019; 
https://resdac.org/cms-data/files/mbsf-base/data-documentation.
42.
Fizazi KT, Namphuong; Fein, Luis Enrique; et al. . LATITUDE: A phase III, double-
blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus 
prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive 
prostate cancer. J Clin Oncol. 2017.
43.
Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with 
newly diagnosed high-risk metastatic castration-sensitive prostate cancer 
(LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 
trial. Lancet Oncol. 2019;20(5):686-700.
44.
Mues KE, Liede A, Liu J, et al. Use of the Medicare database in epidemiologic and 
health services research: a valuable source of real-world evidence on the older and 
disabled populations in the US. Clin Epidemiol. 2017;9:267-277.

Enzalutamide
C3431046 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 09 August 2022
PFIZER CONFIDENTIAL
Page 47 of 47
45.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic 
castration-resistant prostate cancer: final overall survival analysis of the COU-AA-
301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 
2012;13(10):983-992.
46.
Wallace K, Landsteiner A, Bunner S, Engel-Nitz N, Luckenbaugh A. Epidemiology 
and mortality of metastatic castration-resistant prostate cancer (mCRPC) in a 
managed care population in the United States. In: American Society of Clinical 
Oncology; 2020.
47.
Robins JM, Hernan MA, Brumback B. Marginal structural models and causal 
inference in epidemiology. Epidemiology. 2000;11(5):550-560.
48.
Cole SR, Hernan MA. Constructing inverse probability weights for marginal 
structural models. Am J Epidemiol. 2008;168(6):656-664.
49.
Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of 
Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.